Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.54 |
| ▸ | SAT1 | P21673 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25590629 | 0.89 | GNAI3 (0.62) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL19087023 | 0.89 | GNAI3 (0.62) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL5324869 | 0.85 | SAT1 (0.38) | GNAI3GNAO1GNAI1SAT1NAMPT | |
| SCHEMBL11541786 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL7767956 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL17718455 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL19414059 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL11539085 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL1933069 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 | |
| SCHEMBL1678448 | 0.79 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | GNAI3 190/4885GNAO1 716/4885GNAI1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.